Thermo Fisher Scientific Management
Management criteria checks 2/4
Thermo Fisher Scientific's CEO is Marc Casper, appointed in Oct 2009, has a tenure of 15.58 years. total yearly compensation is $30.45M, comprised of 5.7% salary and 94.3% bonuses, including company stock and options. directly owns 0.035% of the company’s shares, worth $53.90M. The average tenure of the management team and the board of directors is 6.8 years and 10.7 years respectively.
Key information
Marc Casper
Chief executive officer
US$30.4m
Total compensation
| CEO salary percentage | 5.71% |
| CEO tenure | 15.6yrs |
| CEO ownership | 0.03% |
| Management average tenure | 6.8yrs |
| Board average tenure | 10.7yrs |
Recent management updates
Recent updates
Thermo Fisher: Tariffs Hit, Valuation Compensates
May 13Thermo Fisher Scientific: Tariff And Policy Impacts Look Priced In
Apr 24Thermo Fisher Scientific And Its Real Value
Apr 14
The demand for personalized medicine will keep Thermo Fisher Scientific thriving
Resilient Demand for Life Sciences & Diagnostics – TMO is a key supplier for biotech, pharma, and research institutions, ensuring steady demand despite economic cycles.Thermo Fisher Scientific: Strong Q4, Strategic M&A, And Poised For Growth In Life Sciences
Mar 07Earnings Preview: Thermo Fisher Is Facing Way Too Many Headwinds
Jan 29Biologicals Is The Future In Thermo Fisher: Buy Rating
Jan 22An Intrinsic Calculation For Thermo Fisher Scientific Inc. (NYSE:TMO) Suggests It's 31% Undervalued
Jan 18
Does Thermo Fisher Scientific (NYSE:TMO) Have A Healthy Balance Sheet?
Dec 31Thermo Fisher Scientific Inc.'s (NYSE:TMO) Share Price Not Quite Adding Up
Dec 13Thermo Fisher Scientific: Renewed Growth Momentum After The Pandemic
Dec 10Thermo Fisher: M&A And Innovation To Drive Sales Growth
Dec 04Thermo Fisher Scientific: Near The Bottom And Attractively Valued
Nov 14Thermo Fisher Scientific Q3: Expecting Market Recovery In FY25; Upgrade To 'Buy'
Oct 23Thermo Fisher Scientific: Fantastic Company, Rich Valuation
Oct 04These 4 Measures Indicate That Thermo Fisher Scientific (NYSE:TMO) Is Using Debt Reasonably Well
Sep 21Thermo Fisher Scientific Inc.'s (NYSE:TMO) Price Is Out Of Tune With Earnings
Aug 16Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging
Jul 25A Look At The Fair Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)
Jul 11Is Thermo Fisher Scientific (NYSE:TMO) A Risky Investment?
Jun 18Low Yield, High Growth: Unveiling The Power Of Thermo Fisher's Dividends
Jun 07Thermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)
Apr 30CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 29 2025 | n/a | n/a | US$7b |
| Dec 31 2024 | US$30m | US$2m | US$6b |
| Sep 28 2024 | n/a | n/a | US$6b |
| Jun 29 2024 | n/a | n/a | US$6b |
| Mar 30 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$19m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jul 01 2023 | n/a | n/a | US$6b |
| Apr 01 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$28m | US$2m | US$7b |
| Oct 01 2022 | n/a | n/a | US$7b |
| Jul 02 2022 | n/a | n/a | US$7b |
| Apr 02 2022 | n/a | n/a | US$8b |
| Dec 31 2021 | US$21m | US$2m | US$8b |
| Oct 02 2021 | n/a | n/a | US$9b |
| Jul 03 2021 | n/a | n/a | US$9b |
| Apr 03 2021 | n/a | n/a | US$8b |
| Dec 31 2020 | US$26m | US$2m | US$6b |
| Sep 26 2020 | n/a | n/a | US$5b |
| Jun 27 2020 | n/a | n/a | US$4b |
| Mar 28 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$19m | US$2m | US$4b |
| Sep 28 2019 | n/a | n/a | US$4b |
| Jun 29 2019 | n/a | n/a | US$4b |
| Mar 30 2019 | n/a | n/a | US$3b |
| Dec 31 2018 | US$19m | US$1m | US$3b |
Compensation vs Market: Marc's total compensation ($USD30.45M) is above average for companies of similar size in the US market ($USD14.14M).
Compensation vs Earnings: Marc's compensation has increased by more than 20% in the past year.
CEO
Marc Casper (56 yo)
Mr. Marc N. Casper has been the Chief Executive Officer and President of Thermo Fisher Scientific, Inc. since October 15, 2009 and has been its Chairman of the Board of Directors since February 26, 2020. M...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 15.6yrs | US$30.45m | 0.035% $ 53.9m | |
| Senior VP & CFO | 9.8yrs | US$11.09m | 0.0098% $ 15.3m | |
| Executive VP & COO | 3.3yrs | US$12.78m | 0.0036% $ 5.7m | |
| Executive VP and President of Laboratory Product & BioProduction | 11.3yrs | US$8.53m | 0.0022% $ 3.4m | |
| Executive VP and President of Life Science | no data | US$11.34m | 0.0060% $ 9.4m | |
| VP & Chief Accounting Officer | 4.2yrs | no data | 0.00052% $ 812.2k | |
| Senior VP & Chief Information Officer | 6.3yrs | no data | no data | |
| Chief Scientific Officer | 3.8yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| Senior VP & General Counsel | 7.3yrs | US$3.12m | 0.0024% $ 3.7m | |
| VP & Chief Communications Officer | 4.6yrs | no data | no data | |
| Chief Human Resources Officer & Senior VP | 8.2yrs | US$2.89m | 0.0038% $ 6.0m |
Experienced Management: TMO's management team is seasoned and experienced (6.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 15.6yrs | US$30.45m | 0.035% $ 53.9m | |
| Independent Lead Director | 18.5yrs | US$406.52k | 0.019% $ 30.0m | |
| Independent Director | 6.5yrs | US$325.84k | 0.00066% $ 1.0m | |
| Independent Director & Member of Scientific Advisory Board | 13.2yrs | US$337.98k | 0.0022% $ 3.4m | |
| Independent Director | 14.4yrs | US$365.84k | 0.0037% $ 5.8m | |
| Member of Scientific Advisory Board & Director | 16yrs | US$345.84k | 0.0021% $ 3.3m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.7yrs | US$353.34k | 0.00032% $ 499.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 8.2yrs | US$354.02k | 0.0011% $ 1.7m | |
| Independent Director | 4.5yrs | US$326.98k | 0.00032% $ 499.8k | |
| Member of Scientific Advisory Board | 6.6yrs | no data | no data |
Experienced Board: TMO's board of directors are seasoned and experienced ( 10.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/21 16:53 |
| End of Day Share Price | 2025/05/21 00:00 |
| Earnings | 2025/03/29 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Thermo Fisher Scientific Inc. is covered by 53 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kadambari Daptardar | Accountability Research Corporation |
| David Toung | Argus Research Company |
| Catherine Ramsey Schulte | Baird |